Mechanistic Models Describing Active Renal Reabsorption and Secretion: A Simulation-Based Study
- 30 November 2012
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 15 (1) , 278-287
Abstract
The objective of the present study was to evaluate mechanistic pharmacokinetic models describing active renal secretion and reabsorption over a range of Michaelis–Menten parameter estimates and doses. Plasma concentration and urinary excretion profiles were simulated and renal clearance (CLr) was calculated for two pharmacokinetic models describing active renal reabsorption (R1/R2), two models describing active secretion (S1/S2), and a model containing both processes. A range of doses (1–1,000 mg/kg) was evaluated, and V max and K m parameter estimates were varied over a 100-fold range. Similar CLr values were predicted for reabsorption models (R1/R2) with variations in V max and K m. Tubular secretion models (S1/S2) yielded similar relationships between Michaelis–Menten parameter perturbations and CLr, but the predicted CLr values were threefold higher for model S1. For both reabsorption and secretion models, the greatest changes in CLr were observed with perturbations in V max, suggesting the need for an accurate estimate of this parameter. When intrinsic clearance was substituted for Michaelis–Menten parameters, it failed to predict similar CLr values even within the linear range. For models S1 and S2, renal secretion was predominant at low doses, whereas renal clearance was driven by fraction unbound in plasma at high doses. Simulations demonstrated the importance of Michaelis–Menten parameter estimates (especially V max) for determining CLr. K m estimates can easily be obtained directly from in vitro studies. However, additional scaling of in vitro V max estimates using in vitro/in vivo extrapolation methods are required to incorporate these parameters into pharmacokinetic models.Keywords
This publication has 31 references indexed in Scilit:
- Transporter-Mediated Drug–Drug InteractionsPharmacogenomics, 2011
- Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiportersBiochemical Pharmacology, 2007
- Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical ImplicationsPharmaceutical Research, 2007
- Renal Tubular Drug TransportersNephron Physiology, 2006
- Comparison of urinary excretion of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: involvement of primary active organic anion transporter.2004
- Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factorsXenobiotica, 2004
- Contribution of Organic Anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in RatThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Cellular and molecular aspects of drug transport in the kidneyKidney International, 2000
- Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney.The Journal of Pharmacology and Experimental Therapeutics, 1984
- Pharmacokinetic Evidence for Saturable Renal Tubular Reabsorption of RiboflavinJournal of Pharmaceutical Sciences, 1970